TELA Bio, Inc. TELA
0.80 USD 0.00 (+0.34%)
At closeNov 3, 2026, 4:02 PM EST
0.80 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
0.7832 Day range 0.8799
0.56 52-week range 1.41
- YTD
- -32.03%
- 1 year
- -41.46%
News
globenewswire.com TELA Bio to Announce Third Quarter 2026 Financial Results MALVERN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…
seekingalpha.com TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript
globenewswire.com TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…
benzinga.com 5 Stock Picks Last Week From Wall Street's Most Accurate Analysts U.S. stocks rose as oil fell on Strait of Hormuz hopes; Benzinga highlights top analysts’ picks: OKTA, AKAM and TELA.
benzinga.com Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2 Craig-Hallum analyst Chase Knickerbocker initiates coverage on TELA Bio (NASDAQ:TELA) with a Buy rating and announces Price Target of $2.
defenseworld.net Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) Director Joseph Capper bought 25,000 shares of TELA Bio stock in a transaction that occurred on Thursday, September 17th. The shares were acquired at…
defenseworld.net TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis Baxter International (NYSE: BAX - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies…
benzinga.com TELA Bio Announces $17M Annual Expense Reduction Through 20% Workforce Streamlining and Resource Optimization, Extending Cash Runway Into 2028 TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca,…
benzinga.com TELA Bio COO And CFO Roberto Cuca To Step Down Effective Immediately TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca,…
globenewswire.com TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader…
seekingalpha.com TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
zacks.com TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.
benzinga.com TELA Bio Q2 EPS $(0.20) Misses $(0.18) Estimate, Sales $19.291M Miss $20.008M Estimate TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.22)…
globenewswire.com TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…
benzinga.com TELA Bio Appoints Heather Getz CEO, Effective Immediately TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors
globenewswire.com TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…
globenewswire.com TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…
globenewswire.com TELA Bio to Announce Second Quarter 2026 Financial Results MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
seekingalpha.com TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
zacks.com TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.25 per share a year ago.
benzinga.com TELA Bio Q1 2026 Earnings Call Transcript 
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com TELA Bio Q1 EPS $(0.21) Misses $(0.18) Estimate, Sales $19.059M Beat $18.597M Estimate TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 16 percent increase over losses of $(0.25) per…
globenewswire.com TELA Bio Reports First Quarter 2026 Financial Results MALVERN, Pa. , May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today…
benzinga.com Earnings Scheduled For May 12, 2026 
globenewswire.com TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
globenewswire.com TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today…
globenewswire.com TELA Bio to Announce First Quarter 2026 Financial Results MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction…
benzinga.com Citizens Maintains Market Outperform on TELA Bio, Lowers Price Target to $3 Citizens analyst David Turkaly maintains TELA Bio (NASDAQ:TELA) with a Market Outperform and lowers the price target from $5 to $3.
defenseworld.net TELA Bio Q4 Earnings Call Highlights TELA Bio (NASDAQ: TELA) reported fourth-quarter and full-year 2025 results that management characterized as a period of "meaningful strategic change," marked by a major rebuild of its U.S. commercial…
benzinga.com TELA Bio Analysts Cut Their Forecasts After Q4 Results TELA Bio (NASDAQ:TELA) reported mixed Q4 results, with higher losses but lower sales than expected. Analysts lowered price targets for the stock.
benzinga.com Amazon To Rally Around 49%? Here Are 10 Top Analyst Forecasts For Wednesday Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC Wainwright, Susquehanna, Raymond James and Goldman Sachs adjust price targets for companies like…
benzinga.com Piper Sandler Maintains Neutral on TELA Bio, Lowers Price Target to $1 Piper Sandler analyst Matt O'Brien maintains TELA Bio (NASDAQ:TELA) with a Neutral and lowers the price target from $1.25 to $1.- benzinga.com Lake Street Maintains Buy on TELA Bio, Lowers Price Target to $2 Lake Street analyst Frank Takkinen maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $3 to $2.
- benzinga.com Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $2 Canaccord Genuity analyst Caitlin Roberts maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $4 to $2.
- benzinga.com TELA Bio Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $20.869M Miss $21.047M Estimate TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 26.09 percent increase over losses of $(0.23) per…
- benzinga.com Earnings Scheduled For March 24, 2026
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Earnings Scheduled For August 11, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Earnings Scheduled For May 8, 2025